Protein Biotechnologies,Inc。是生物产品的专业制造商,也是生命科学研究界的合同实验室服务提供商。我们的活动为从人体临床组织标本获得的分子衍生物(RNA,DNA和蛋白质)产品提供基础研究,临床研究和药物发现和开发市场。我们的产品支持癌症,神经退行性疾病,心血管疾病,糖尿病,肥胖,传染病,炎症和自身免疫的分子机制研究。我们的产品组合包括用于高通量蛋白质生物标记物筛选的反相蛋白质微阵列,用于研究人类临床标本中基因和蛋白质表达的组织微阵列,以及临床定义的大即用型临床试验集合之一,病理学验证的人体标本衍生物,用于生物标志物分析应用。我们为范围内的广泛客户提供产品和服务 - 来自学术和政府研究机构; 生物技术和制药公司。
Protein Biotechnologies汇集了市场上大,全面的即用型人体蛋白质提取物。这些组织裂解物是生物标记物鉴定/筛选,抗体检测/表征,蛋白质 - 蛋白质相互作用,蛋白质表达,配体结合,ELISA,免疫沉淀,1D和2D凝胶电泳以及蛋白质印迹的理想选择。
蛋白质生物技术遵循严格的生物伦理学标准,根据IRB批准的方案收集所有标本,确保患者的机密性,安全性和知情同意。
将人体组织样品在移除后5-10分钟内快速冷冻至-120℃,确保样品具有高质量。目前可用的标本包括:
价格 |
正常裂解液:$ 125.00 / 100 ug |
肿瘤裂解液:175.00美元/ 100微克 |
Nor./Tum。套装:270.00美元(9折优惠) |
折扣 |
2-8个小瓶10% |
9-20小瓶15% |
> 20小瓶20% |
膀胱癌的组织学类型包括:
超过90%的膀胱癌是来自尿路上皮的移行细胞癌。约6%至8%是鳞状细胞癌,2%是腺癌。腺癌可以是urachal起源,也可以是nonurachal起源; 后一种类型通常被认为是由长期受刺激的过渡上皮的化生引起的。病理分级基于细胞异型性,核异常和有丝分裂数量,具有重要的预后意义。
Human Bladder Cancer Lysates | ||||||
Catalog Number | Diagnosis | Grade | Stage | TNM | Sex | Age |
T10-001 | Transitional cell carcinoma | n/a | I | T1bNxM0 | F | 57 |
T10-002 | Papillary transitional cell carcinoma | 1 | II | T2NxM0 | M | 56 |
T10-003 | Transitional cell carcinoma | 2 | II | T2NxM0 | M | 64 |
T10-004 | Epidermoid carcinoma | 2 | III | T3N0M0 | M | 71 |
T10-005 | Papillary transitional cell carcinoma | n/a | n/a | n/a | M | 52 |
T10-006 | Transitional cell carcinoma | 1 | II | T2bN0M0 | M | 42 |
T10-007 | Squamous cell carcinoma | 2 | III | T3NxM0 | M | 39 |
T10-008 | Transitional cell carcinoma | 1 | III | T3NxM0 | F | 45 |
T10-009 | Transitional cell carcinoma | 2 | II | T2bmN0M0 | F | 52 |
T10-010 | Transitional cell carcinoma | 3 | II | T2bNxM0 | M | 70 |
T10-011 | Squamous cell carcinoma | 3 | II | T2NxM0 | M | 54 |
T10-012 | Squamous cell carcinoma | 2 | II | T2bNxM0 | M | 62 |
T10-013 | Adenocarcinoma | 3 | II | T2mNxM0 | M | 74 |
T10-014 | Transitional cell carcinoma | 2 | II | T2NxM0 | M | 39 |
T10-015 | Transitional cell carcinoma | n/a | II | T2bNxM0 | M | 57 |
T10-016 | Transitional cell carcinoma, moderately differentiated. | 2 | n/a | n/a | M | 74 |
T10-017 | Transitional cell carcinoma, moderately differentiated. | 2 | n/a | n/a | F | 85 |
T10-018 | Transitional cell carcinoma, moderately differentiated. | 2 | n/a | n/a | M | 76 |
T10-019 | Transitional cell carcinoma, poorly differentiated. | 3 | n/a | n/a | M | 70 |
T10-020 | Transitional cell carcinoma, moderately differentiated. | 2 | n/a | n/a | M | 39 |
T10-021 | Transitional cell carcinoma, moderately differentiated. | 2 | n/a | n/a | M | 29 |
T10-022 | Transitional cell carcinoma, poorly differentiated. | 3 | n/a | T3bNxMx | M | 70 |
T10-023 | Adenocarcinoma, moderately differentiated. | 2 | n/a | n/a | M | 43 |
T10-024 | Transitional cell carcinoma, poorly differentiated. | 3 | n/a | n/a | M | 62 |
T10-025 | Transitional cell carcinoma, poorly differentiated. | 3 | n/a | n/a | M | 62 |
T10-026 | Transitional cell carcinoma, moderately differentiated. | 3 | n/a | n/a | M | 63 |
T10-027 | Transitional cell carcinoma, poorly differentiated. | 3 | n/a | n/a | M | 39 |
T10-028 | Transitional cell carcinoma, poorly differentiated. | 3 | n/a | n/a | M | 75 |
T10-029 | Transitional cell carcinoma, well differentiated. | 1 | n/a | n/a | M | 71 |
T10-030 | Adenocarcinoma, poorly differentiated. | 3 | n/a | n/a | M | 67 |
参考文献:
Mostofi FK,Davis CJ,Sesterhenn IA:泌尿道肿瘤的病理学。在:Skinner DG,Lieskovsky G,编辑:泌尿生殖系统癌症的诊断和管理。Philadelphia,Pa:WB Saunders,1988。,pp 83-117。
Wilson TG,Pritchett TR,Lieskovsky G,et al。:膀胱原发性腺癌。泌尿外科38(3):223-6,1991。
LiVolsi VA:甲状腺疾病的病理学。在:Falk SA:甲状腺疾病:内分泌学,外科学,核医学和放射治疗。宾夕法尼亚州费城:Lippincott-Raven,1997年,第127-175页。
电话
QQ咨询
4006551678